Literature DB >> 32112932

Comparison of thermosensitive in situ gels and drug-resin complex for ocular drug delivery: in vitro drug release and in vivo tissue distribution.

Yidan Wei1, Conghao Li1, Qiang Zhu1, Xin Zhang1, Jian Guan1, Shirui Mao2.   

Abstract

Conventional ophthalmic eye drops are limited by their rapid elimination rate and short time of action. Ion exchange resin has been used to achieve sustained ocular drug delivery but the high selectivity of drug molecules restricts its broad application. In situ gel system seems to be a good strategy to address these problems but the influence of in situ gel type on the sustained release behavior and tissue distribution after ocular application is unclear. Therefore, in this study, using betaxolol hydrochloride as a model drug, poloxamer 407 and methylcellulose as the carriers, two thermosensitive in situ gel systems were prepared and characterized. Influence of formulation composition type and concentration on in vitro drug release was studied. Tissue distribution after ocular delivery of two different thermosensitive in situ gels was studied and compared with commercial BH eye drop (Betoptic S®). In vitro studies demonstrated that addition of 4% HPMC 606W in 15% P407 solution and 5% PEG4000 in 2% MC solution obtained gels with appropriate gelation temperature and similar sustained drug release rate. In vivo tissue distribution study indicated that they presented similar drug concentration in cornea, iris-ciliary and aqueous humor irrespective of gel type, with higher drug concentration achieved after 4 h compared to the commercial resin suspension eye drops. The AUC and MRT of the two in situ gel eye drops were 2 times higher than that of the commercial resin suspension eye drops in cornea. In conclusion, the two thermosensitive in situ gels have prolonged drug release after ocular drug delivery compared with ion exchange resin eye drops, implying their potential applications in clinic with broad drug adoptability.
Copyright © 2020. Published by Elsevier B.V.

Entities:  

Keywords:  Betaxolol hydrochloride; In situ gel; Methylcellulose; Ophthalmic delivery; Poloxamer 407; Tissue distribution

Year:  2020        PMID: 32112932     DOI: 10.1016/j.ijpharm.2020.119184

Source DB:  PubMed          Journal:  Int J Pharm        ISSN: 0378-5173            Impact factor:   5.875


  7 in total

1.  Design and Optimization of In Situ Gelling Mucoadhesive Eye Drops Containing Dexamethasone.

Authors:  Boglárka Szalai; Orsolya Jójárt-Laczkovich; Anita Kovács; Szilvia Berkó; György Tibor Balogh; Gábor Katona; Mária Budai-Szűcs
Journal:  Gels       Date:  2022-09-02

Review 2.  Nanomaterials based on thermosensitive polymer in biomedical field.

Authors:  Yingshu Guo; Li Sun; Yajing Wang; Qianqian Wang; Dan Jing; Shiwei Liu
Journal:  Front Chem       Date:  2022-09-21       Impact factor: 5.545

3.  Formulation of Ocular In Situ Gels with Lithuanian Royal Jelly and Their Biopharmaceutical Evaluation In Vitro.

Authors:  Kristina Perminaite; Mindaugas Marksa; Monika Stančiauskaitė; Tadas Juknius; Aidas Grigonis; Kristina Ramanauskiene
Journal:  Molecules       Date:  2021-06-10       Impact factor: 4.411

Review 4.  The Emerging Role of Topical Ocular Drugs to Target the Posterior Eye.

Authors:  Lixiang Wang; Mikael Ben Zhou; Hui Zhang
Journal:  Ophthalmol Ther       Date:  2021-07-04

5.  Ophthalmic In Situ Gels with Balsam Poplar Buds Extract: Formulation, Rheological Characterization, and Quality Evaluation.

Authors:  Monika Stanciauskaite; Mindaugas Marksa; Liudas Ivanauskas; Kristina Perminaite; Kristina Ramanauskiene
Journal:  Pharmaceutics       Date:  2021-06-24       Impact factor: 6.321

Review 6.  Topical Drug Delivery to the Posterior Segment of the Eye.

Authors:  Marina Löscher; Chiara Seiz; José Hurst; Sven Schnichels
Journal:  Pharmaceutics       Date:  2022-01-06       Impact factor: 6.321

Review 7.  Stimuli-Responsive Polymers for Transdermal, Transmucosal and Ocular Drug Delivery.

Authors:  Dmitriy Berillo; Zharylkasyn Zharkinbekov; Yevgeniy Kim; Kamila Raziyeva; Kamila Temirkhanova; Arman Saparov
Journal:  Pharmaceutics       Date:  2021-12-01       Impact factor: 6.321

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.